Sector News

Medtronic to Acquire RF Surgical for $235 Million

July 15, 2015
Life sciences
Medtronic PLC agreed to acquire RF Surgical Systems Inc. for roughly $235 million, the latest in a string of smaller deals since the medical-device maker’s acquisition of Covidien.
 
Carlsbad, Calif.-based RF Surgical makes products that focus on counting items used during surgery—such as surgical sponges, gauze or towels—to help prevent them from being left in the patient during surgery, which can lead to serious complications.
 
RF Surgical’s system uses a low radio frequency signal to track and detect surgical gauze, sponges and towels, which are embedded with an RF tag, through blood, dense tissue and bone.
 
The deal, expected to close next month, is expected to meet Medtronic’s long-term financial metrics for acquisitions, though the deal’s effect on yearly earnings isn’t expected to be material.
 
Medtronic last month agreed to acquire privately held medical-device company Aptus Endosystems Inc. for roughly $110 million and cardiac-mapping company CardioInsight Technologies Inc. in a deal valued at $93 million.
 
Also in June, Medtronic reported a net loss of $1 million in its first combined quarter with Covidien, largely because of $880 million in charges for the Covidien acquisition and a $329 million expense from the resolution of a tax dispute with the Internal Revenue Service.
 
By Tess Stynes
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach